Heparin-Natrium Braun (Heparin Sodium)

Heparin-Natrium Braun is indicated for several thrombo‑embolic conditions where anticoagulation is required.

• Prevention of deep‑vein thrombosis (DVT) in patients undergoing major surgery or who are immobilized for prolonged periods.
• Treatment and prophylaxis of pulmonary embolism, reducing the risk of life‑threatening blockage of pulmonary arteries.
• Management of acute coronary syndrome, including unstable angina and myocardial infarction, to limit clot propagation in coronary vessels.
• Prevention of clot formation during cardiac or vascular interventional procedures such as angioplasty, stent placement, or bypass grafting.
• Use in patients with atrial fibrillation who have an elevated risk of stroke, although this may be considered off‑label in certain jurisdictions.
• Adjunct anticoagulation during extracorporeal circulation procedures such as cardiopulmonary bypass or hemodialysis to maintain circuit patency.

Adverse reactions to Heparin‑Natrium Braun vary in frequency and severity; they are reported in clinical practice and post‑marketing surveillance.

Common

• Minor bleeding at the injection site.
• Bruising or hematoma formation around the administration area.
• Nausea or mild gastrointestinal discomfort.
• Transient elevation of liver enzymes detected on routine labs.
• Injection site pain, erythema, or localized swelling.

Serious

• Major hemorrhage, including internal bleeding or severe external bleeding.
• Heparin‑induced thrombocytopenia (HIT) with a rapid drop in platelet count.
• Allergic reactions ranging from urticaria to anaphylaxis.
• Spontaneous spinal or epidural hematoma causing neurologic deficits.
• Acute adrenal hemorrhage leading to adrenal insufficiency.

Before initiating Heparin‑Natrium Braun, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Assess individual bleeding risk, including recent surgery, trauma, or active gastrointestinal bleeding.
• Review baseline platelet count and coagulation parameters such as aPTT and PT/INR before starting therapy.
• Use reduced initial doses in patients with significant renal or hepatic impairment.
• Avoid use in individuals with known hypersensitivity to heparin or pork‑derived products.
• Monitor platelet counts regularly for signs of heparin‑induced thrombocytopenia during treatment.
• Adjust dosing or discontinue therapy if uncontrolled bleeding or severe thrombocytopenia occurs.

Heparin‑Natrium Braun may interact with other agents that affect hemostasis or drug metabolism; awareness of these interactions helps prevent adverse events.

Avoid

• Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without appropriate dose adjustment.
• Combination with antiplatelet agents such as aspirin, clopidogrel, or ticagrelor.
• Concomitant administration of fibrinolytic drugs (e.g., alteplase, streptokinase) that increase bleeding risk.
• Use together with non‑steroidal anti‑inflammatory drugs (NSAIDs) that can potentiate hemorrhage.

Use with caution

• Dual therapy with low‑molecular‑weight heparins or fondaparinux, requiring close laboratory monitoring.
• Concurrent use of selective serotonin reuptake inhibitors (SSRIs) or other medications that impair platelet function.
• Overlap with high‑dose vitamin K antagonists (e.g., warfarin) where INR monitoring is essential.